Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma

Clinical and Experimental Immunology

Volumn 139, Issue 3, 2005, Pages 429-438

  Matsushita, Mariko ^a   Yamamoto, T ^a   Nishioka, K ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bleomycin; Mouse model; PAI 1; Scleroderma; TGF

Indexed keywords

BLEOMYCIN; MESSENGER RNA; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; EXTRACELLULAR MATRIX; FIBROBLAST; HISTOPATHOLOGY; MACROPHAGE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SCLERODERMA; SKINFOLD THICKNESS;

ANIMALS; BLEOMYCIN; COLLAGEN; DERMIS; FEMALE; FIBROBLASTS; HISTOCYTOCHEMISTRY; MACROPHAGES; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MODELS, ANIMAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 14744306219     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02718.x     Document Type: Article

References (37)

1. Roberts AB, Sporn MB. The transforming growth factor βs. In: Sporn MB, Roberts AB, eds. Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors, Vol. 95. New York: Springer-Verlag, 1990:419-72.
2. Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Transforming growth factor-β increases steady-state levels of type-I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 1987; 79:1285-8.
3. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor β (TGF-β) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 247:597-604.
4. Ignotz RA, Endo T, Massague J. Regulation of cell adhesion receptors by transforming growth factor-beta. J Biol Chem 1987; 246:389-92.
5. Eitsman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97:232-7.
6. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000; 157:177-87.
7. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator on cultured human lung fibroblasts by transforming growth factor beta. J Cell Biol 1986; 103:2403-10.
8. Laiho M, Saksela O, Keske-Oja J. Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 1986; 164:399-407.
9. Laiho M, Saksela O, Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor: Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem 1987; 262:17467-74.
10. Heat JK. Transforming growth factor beta modulates the expression of collagenase and metalloproteinases inhibitor. EMBO J 1987; 6:1899-904.
11. Denner S, Itoh S, Vivien D, Dijke PT, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17:3091-100.
12. Gong R, Rifai A, Tolbert EM, Centracchio JN, Dworkin LD. Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol 2003; 14:3047-60.
13. Zhang LP, Takahara T, Yata Y, Furui K, Jin B, Kawada N, Watanabe A. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: Role of stellate cells. J Hepatol 1999; 31:703-11.
14. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96:1621-30.
15. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 15:493-504.
16. Sisson TH, Hattori N, Xu Y, Simon RH. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes. Hum Gene Ther 1999; 10:2315-23.
17. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med 1996; 2:287-92.
18. Chan JC, Duszczyszyn DA, Castellino FJ, Ploplis VA. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001; 159:1681-8.
19. Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999; 112:456-62.
20. V mice. J Rheumatol 1999; 26:2628-34.
21. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III. Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000; 292:535-41.
22. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV. Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001; 117:999-1001.
23. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V. Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002; 102:77-83.
24. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of plasminogen/plasmin and matrix metalloproteinases systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18:1035-45.
25. Keski-Oja J, Raghow R, Sawdey M, Loskutoff DJ, Postlethwaite AE, Kang AH, Moses HL. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type Tprocollagen by transforming growth factor-beta: Divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 1988; 263:3111-5.
26. Overall CM, Wrana JL, Sodek J. Transforming growth factor-beta regulation of collagenase, 72 kDa-progelatinase, TIMP and PAI-1 expression in rat bone cell populations and human fibroblasts. Connect Tissue Res 1989; 20:289-94.
27. Wright JK, Cawston TE, Hazleman BL. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta 1991; 1094:207-10.
28. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Meta 1998; 24:111-9.
29. Higgins PJ, Slack JK, Diegelmann RF, Staiano-Coico L. Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype. Exp Cell Res 1999; 248:634-42.
30. Tuan TL, Zhu JY, Sun B, Nichter LS, Nimni ME, Laug WE. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. J Invest Dermatol 1996; 106:1007-11.
31. Dong C, Zhu S, Wang T et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99:3908-13.
32. Ames PRJ, Lupolo S, Alves J et al. The coagulation/fibrinolysis balance in systemic sclerosis: Evidence for a haematological stress syndrome. Br J Rheumatol 1997; 36:1045-50.
33. Lee P, Norman CS, Sukenik S, Alderdice CA. The clinical significance of coagulation abnormalities in systemic sclerosis (scleroderma). J Rheumatol 1985; 12:514-7.
34. Woessner JF, Nagase H. Matrix Metalloproteinases and Timps. Oxford: Oxford University Press, 1996.
35. Hertig A, Berrou J, Allory Y, Breton L, Commo F, Costa De Beauregard MA, Carmeliet P, Rondeau E. Type 1 plasminogen activator inhibitor deficiency aggravates the course experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 2003; 17:1904-6.
36. Kolb M, Bonniaud P, Galt T, Sime PJ, Kelly MM, Margetts PJ, Gauldie J. Differences in the fibrogenic response after transfer of active transforming growth factor-β1 gene to lungs of 'fibrosis-prone' and 'fibrosis-resistant' mouse strains. Am J Respir Cell Mol Biol 2002; 27:141-50.
37. Kruithof EK, Vassalli JD, Schleuning WD, Mattaliano RJ, Bachmann F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986; 261:11207-13.